Dr. Reddy's Laboratories Limited (BOM:500124)
India · Delayed Price · Currency is INR | Market Cap | 1.04T |
| Revenue (ttm) | 334.26B |
| Net Income (ttm) | 56.80B |
| Shares Out | 832.40M |
| EPS (ttm) | 68.11 |
| PE Ratio | 18.29 |
| Forward PE | 20.36 |
| Dividend | 8.00 (0.65%) |
| Ex-Dividend Date | Jul 10, 2025 |
| Volume | 90,629 |
| Average Volume | 97,972 |
| Open | 1,240.10 |
| Previous Close | 1,234.40 |
| Day's Range | 1,240.10 - 1,263.85 |
| 52-Week Range | 1,025.90 - 1,404.60 |
| Beta | 0.33 |
| RSI | 43.42 |
| Earnings Date | Oct 24, 2025 |
About Dr. Reddy's Laboratories
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages i... [Read more]
Financial Performance
In 2024, Dr. Reddy's Laboratories's revenue was 325.54 billion, an increase of 16.61% compared to the previous year's 279.16 billion. Earnings were 56.54 billion, an increase of 1.54%.
Financial StatementsNews
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
The Trump administration is reportedly planning to exclude imported generic drugs from tariffs. White House spokesman Kush Desai told the Wall Street Journal that "the administration is not actively d...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Bullish Two Hundred Day Moving Average Cross - RDY
In trading on Monday, shares of Dr. Reddy's Laboratories Ltd. (Symbol: RDY) crossed above their 200 day moving average of $14.22, changing hands as high as $14.23 per share. Dr. Reddy's Laboratories L...
ESPR Settles Nexletol/Nexlizet Patent Litigation With RDY, Stock Up
Esperion settles Nexletol and Nexlizet patent dispute with Dr. Reddy's, securing U.S. market exclusivity until 2040 and lifting its shares nearly 14%.
Esperion Therapeutics (ESPR) Settles Patent Dispute with Dr. Reddy's
Esperion Therapeutics (ESPR) Settles Patent Dispute with Dr. Reddy's
Esperion settles patent dispute with Dr. Reddy’s over cholesterol drugs
Esperion settles with Dr. Reddy’s, delaying generic NEXLETOL/NEXLIZET until 2040.
Dr. Reddy's (RDY) Reaches Settlement in Patent Dispute with Esperion
Dr. Reddy's (RDY) Reaches Settlement in Patent Dispute with Esperion
Nifty 50 top losers today, September 29: Axis Bank, Maruti Suzuki, Dr. Reddy’s Laboratories, Adani Enterprises, HDFC Life and more
Indian equity markets closed marginally lower on September 29 after a volatile session. The Sensex slipped 61.52 points, or 0.08%, to 80,364.94, while the Nifty 50 fell 19.80 points, or 0.08%, to 24,6...
Trump’s 100% tariffs on branded drugs: Which Indian pharma stocks are most vulnerable? Experts weigh in
Donald Trump's tariff move impacts Indian pharma stocks. Companies like Sun Pharma, Cipla, and Dr. Reddy's face potential declines. US represents a major market for Indian exports.
Dr. Reddy’s shares slip over 2% as Trump’s 100% pharma tariff triggers sector-wide selloff
Shares of Dr. Reddy’s Laboratories fell 2.09% to ₹1,248.10 on Friday, as the broader pharmaceutical sector came under pressure following U.S. President Donald Trump’s announcement of a 100% tariff on ...
Gland Pharma down 4%, Sun Pharma slips 2.6%, Dr Reddy’s down 2%, Zydus nearly 3%, Aurobindo down 2% as Trump’s 100% pharma tariff jolts sector
Indian pharmaceutical stocks came under heavy selling pressure on Friday, September 26, after U.S. President Donald Trump announced a 100% tariff on imports of branded and patented pharmaceutical drug...
Indian pharma stocks in focus as Trump announces 100% tariff on branded drugs
Indian pharma shares such as Sun Pharma, Lupin, Dr. Reddy’s, Cipla, and Aurobindo Pharma are in focus after Donald Trump announced a 100% tariff on imported branded drugs, effective October 1, unless ...
Dr. Reddy's Receives Positive CHMP Opinion For AVT03
(RTTNews) - Dr. Reddy's Laboratories (DRREDDY, RDY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing ...
Dr. Reddy's (RDY) Set to Market New AVT03 Biosimilar in Europe
Dr. Reddy's (RDY) Set to Market New AVT03 Biosimilar in Europe
Dr Reddy shares in focus: India bulk drug makers reportedly start preparing for Ozempic patent expiry
Dr. Reddy’s Laboratories Ltd. shares were in focus today after reports suggested that Indian bulk drug makers are preparing for the upcoming expiry of Novo Nordisk A/S’s patents on its blockbuster wei...
Dr. Reddy’s launches novel molecule ‘Tegoprazan’ in India for acid-related gastrointestinal diseases
Dr. Reddy’s Laboratories Ltd. on Tuesday announced the launch of its novel patented molecule, Tegoprazan, in India under the brand name PCAB®, marking a major step forward in the treatment of acid-rel...
Nifty 50 top losers today, September 15: Cipla, Asian Paints, Mahindra & Mahindra, Shriram Finance, Dr. Reddy’s and more
Indian equity markets ended on a subdued note on September 15, with benchmark indices slipping in a rangebound session. The Sensex fell 118.96 points, or 0.15 percent, to 81,785.74, while the Nifty cl...
Dr. Reddy’s shares fall nearly 2% after USFDA issues Form 483 with 5 observations for Hyderabad unit
Shares of Dr. Reddy’s Laboratories slipped 1.65% to ₹1,295 on Monday, September 15, after the company confirmed that the US Food & Drug Administration (USFDA) issued a Form 483 with five observations ...
Stocks in news today, Sept 15: HUL, HAL, Dr Reddy’s, Apollo Hospitals, Adani Power, APL, Engineers India, Railtel among key shares
Indian equities will track a busy day of corporate developments with several companies announcing orders, partnerships, and regulatory updates. A broad list of stocks is expected to remain in focus on...
Dr. Reddy’s Laboratories receives Form 483 with five observations from USFDA after Bachupally facility inspection
Dr. Reddy’s Laboratories has announced that the United States Food & Drug Administration (USFDA) has issued a Form 483 with five observations following a Pre-Approval Inspection (PAI) at its biologics...
Dr. Reddy’s Laboratories acquires STUGERON portfolio from Janssen Pharmaceutica for $50.5 million
Dr. Reddy’s Laboratories Limited, has entered a definitive agreement to acquire the STUGERON® portfolio from Janssen Pharmaceutica NV, an affiliate of Johnson & Johnson, for USD 50.5 million. The acqu...
Nifty 50 top gainers today, September 9: Infosys, Dr. Reddy’s Laboratories, Wipro, Adani Ports and more
Indian equity benchmarks closed on a strong note on Monday, September 9, with the Nifty 50 inching closer to the 24,900 mark. The Sensex added 314.02 points to end at 81,101.32, while the Nifty settle...
Nifty 50 top losers today, September 8: Trent, Asian Paints, Dr. Reddy’s Laboratories, Nestle India and more
Indian equity benchmarks ended marginally higher in a volatile session on September 8, with gains in select heavyweights helping the indices stay in positive territory. The Sensex closed 76.54 points ...
Dr. Reddy’s Laboratories receives 7 USFDA observations at UK facility inspection
Dr. Reddy’s Laboratories Ltd. announced that the United States Food & Drug Administration (USFDA) has completed a Good Manufacturing Practice (GMP) inspection at its API Mirfield facility in West York...
Top stocks to buy today: Stock recommendations for August 28, 2025 - check list
Top stock market recommendations: Nuvama Professional Clients Group's Aakash K Hindocha recommends Nykaa, Kaynes, and Dr Reddy's Laboratories as top stock picks for today. Nifty faces potential downsi...